Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)

被引：0

作者：

Zack, Debra ^{[1
]}

Baumann, Maria Jaraczewska ^{[2
]}

Korkosz, Mariusz ^{[3
]}

Suljok, Gabriella ^{[4
]}

Sramek, Petr ^{[5
]}

Rojkovich, Bernadette ^{[6
]}

Daniluk, Stafan ^{[7
]}

Bartalos, Janos ^{[8
]}

Foster, Paul ^{[1
]}

机构：

[1] Xencor Inc, San Diego, CA USA

[2] NZOZ Ctr Med HCP, Poznan, Poland

[3] Univ Hosp Krakow, Malopolskie Ctr Med, Krakow, Poland

[4] Drug Res Ctr Ltd, Baltonfured, Hungary

[5] PRA CZ, Prague, Czech Republic

[6] Polyclin Hospitaller Bros St John God, Budapest, Hungary

[7] NZOZ Ctr Osteoporosis & Osteoarticular Dis, Bialystok, Poland

[8] PRA Hungary Ltd, Budapest, Hungary

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2139

引用

页数：2

共 50 条

[1] A PHASE 1B/2A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS
Jaraczewska-Baumann, M.
Korkosz, M.
Sulyok, G.
Sramek, P.
Rojkovich, B.
Daniluk, S.
Bartalos, J.
Zack, D. J.
Foster, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 481 - 481
[2] RESULTS OF A PHASE 1B STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF THE MMP9 INHIBITOR GS-5745 IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Gossage, D. L.
Cieslarova, B.
Ap, S.
Zheng, H.
Zhao, S.
Xin, Y.
Lal, P.
Chen, G.
Smith, V.
Sundy, J. S.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 723 - 724
[3] A Phase 1b/2a Study to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects with Developmental and/or Epileptic Encephalopathies
Asgharnejad, Mahnaz
Paker, Asif
Xu, Rengyi
Lee, Deborah
[J]. NEUROLOGY, 2018, 90
[4] Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Kurrasch, Regina
Brown, Judith C.
Chu, Myron
Craigen, Jenny
Overend, Philip
Patel, Bela
Wolfe, Steven
Chang, David J.
[J]. JOURNAL OF RHEUMATOLOGY, 2013, 40 (07) : 1089 - 1096
[5] Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia
Lin, Tara L.
Wood, Robyn
Ham, Tammy
Sullivan, Taegen
Dandawate, Prasad
Anant, Shrikant
Santaguida, Marianne T.
Toren, Paul
Jensen, Roy A.
Taylor, John A.
Baltezor, Michael Jay
Dalton, Michael
Meyer, Fred
McBride, John
Umbreit, Jay Nicholas
McCulloch, William
Vanderlaag, Kathryn
Wagner, Joseph
Weir, Scott James
Smith, B. Douglas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
Hotchkiss, Richard S.
Colston, Elizabeth
Yende, Sachin
Crouser, Elliott D.
Martin, Greg S.
Albertson, Timothy
Bartz, Raquel R.
Brakenridge, Scott C.
Delano, Matthew J.
Park, Pauline K.
Donnino, Michael W.
Tidswel, Mark
Mayr, Florian B.
Angus, Derek C.
Coopersmith, Craig M.
Moldawer, Lyle L.
Catlett, Ian M.
Girgis, Ihab G.
Ye, June
Grasela, Dennis M.
[J]. INTENSIVE CARE MEDICINE, 2019, 45 (10) : 1360 - 1371
[7] Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
Richard S. Hotchkiss
Elizabeth Colston
Sachin Yende
Elliott D. Crouser
Greg S. Martin
Timothy Albertson
Raquel R. Bartz
Scott C. Brakenridge
Matthew J. Delano
Pauline K. Park
Michael W. Donnino
Mark Tidswell
Florian B. Mayr
Derek C. Angus
Craig M. Coopersmith
Lyle L. Moldawer
Ian M. Catlett
Ihab G. Girgis
June Ye
Dennis M. Grasela
[J]. Intensive Care Medicine, 2019, 45 : 1360 - 1371
[8] Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Lin, Tara L.
Wood, Robyn
Ham, Tammy
Sullivan, Taegen
Bhattacharyya, Sangita
Dandawate, Prasad
Anant, Shrikant
Santaguida, Marianne T.
Zhang, Na
Toren, Paul
Jensen, Roy A.
Taylor, John A.
Baltezor, Michael Jay
Dalton, Michael
McBride, John
Umbreit, Jay Nicholas
McCulloch, William
Vanderlaag, Kathryn
Wagner, Joseph
Weir, Scott James
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis
Wisniacki, Nicolas
Amaravadi, Lakshmi
Galluppi, Gerald R.
Zheng, Timothy S.
Zhang, Ray
Kong, Jessica
Burkly, Linda C.
[J]. CLINICAL THERAPEUTICS, 2013, 35 (08) : 1137 - 1149
[10] Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
Quinn, Tom M.
Gaughan, Erin E.
Bruce, Annya
Antonelli, Jean
O'Connor, Richard
Li, Feng
McNamara, Sarah
Koch, Oliver
MacKintosh, Claire
Dockrell, David
Walsh, Timothy
Blyth, Kevin G.
Church, Colin
Schwarze, Juergen
Boz, Cecilia
Valanciute, Asta
Burgess, Matthew
Emanuel, Philip
Mills, Bethany
Rinaldi, Giulia
Hardisty, Gareth
Mills, Ross
Findlay, Emily Gwyer
Jabbal, Sunny
Duncan, Andrew
Plant, Sinead
Marshall, Adam D. L.
Young, Irene
Russell, Kay
Scholefield, Emma
Nimmo, Alastair F.
Nazarov, Islom B.
Churchill, Grant C.
McCullagh, James S. O.
Ebrahimi, Kourosh H.
Ferrett, Colin
Templeton, Kate
Rannard, Steve
Owen, Andrew
Moore, Anne
Finlayson, Keith
Shankar-Hari, Manu
Norrie, John
Parker, Richard A.
Akram, Ahsan R.
Anthony, Daniel C.
Dear, James W.
Hirani, Nik
Dhaliwal, Kevin
[J]. EBIOMEDICINE, 2022, 76

← 1 2 3 4 5 →